DAPAGLIFLOZINE INTENDED FOR USE IN TREATMENT PROCEDURES FOR HEART FAILURE WITH REDUCED EJECTION FRACTION

Abstract

The present invention relates to methods for treating patients with heart failure with reduced ejection fraction (HFrEF), with or without type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods according to the invention can reduce the risk of a composite endpoint of a first episode of worsening heart failure (hospitalization due to heart failure or emergency room visit due to heart failure) or of death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of hospitalizations due to heart failure and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce the worsening of heart failure symptoms.The methods according to the invention can also improve the symptoms of heart failure, health status and quality of life.